A statement released earlier today by Roth Capital about Mateon Therapeutics (OTCMKTS:MATN) raises the target price to $2.00
- Updated: April 20, 2017
Reporting a possible upside of 1.60%, Roth Capital increased the stock price target of Mateon Therapeutics (OTCMKTS:MATN) to $2.00
On 1/27/2017, Maxim Group released a statement about Mateon Therapeutics (OTCMKTS:MATN) upped the target price from $0.00 to $2.00 that indicated a possible upside of 4.13%.
Yesterday Mateon Therapeutics (OTCMKTS:MATN) traded 10.06% higher at $0.77. Mateon Therapeutics’s 50-day moving average is $0.69 and its two hundred day average is $0.52. With the last stock price close up 46.91% relative to the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the same period. 144,796 shares of the stock exchanged hands, up from an avg. volume of 82,461
See Chart Below
Mateon Therapeutics has 52 week low of $0.27 and a one year high of $1.02 and has a total market value of $0.
About Mateon Therapeutics (OTCMKTS:MATN)
Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor's blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.